Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad

A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 Vaccine

This study is a randomized, blinded, parallel-controlled phase 3 clinical trial. The study intent to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as heterologous booster in participants aged 18 years and older vaccinated 2 doses Inactivated SARS-CoV-2 Vaccine.

Study Overview

• Status: Not yet recruiting
• Conditions: SARS-CoV-2
• Intervention / Treatment: Biological: LVRNA009; Biological: CoronaVac®

• Study Type: Interventional
• Enrollment (Anticipated): 1100
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Fan Zhang; Phone Number: 8066 021-33360772; Email: fan.zhang@aimbio.com
• Study Contact Backup: Name: Wumei Han; Phone Number: 8021 021-33360772; Email: wumei.han@aimbio.com

Study Locations

• Pakistan
  • Islamabad, Pakistan, 45500
    • Clinical Trial Unit, National Institute of Health
    • Contact: Omera Naseer, Dr; Phone Number: 03005302095; Email: omerashuaib@hotmail.com
    • Principal Investigator: Aamer Ikram, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adults aged 18 years and older.
2. Understand the contents of the ICF and voluntarily sign it (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed).
3. Participants who are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures.
4. Female participants of childbearing potential or partners of male participants: voluntarily agree to use effective contraception with their partners 14 days prior to the vaccination and must agree to continue such precautions during the study until 3 months after vaccination. [Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices (IUDs), sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.].
5. For female participants: without childbearing potential (amenorrhea for at least 1 year or documented surgical sterilization) or have used effective contraception with a negative pregnancy test before vaccination in this study.
6. Axillary temperature <37.3°C/99.1°F at screening visit and 72 hours prior to vaccination.
7. Healthy participants or participants with mild underlying disease [in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study].
8. Participants who have vaccinated 2 doses of CoronaVac® (with an interval of 3-8 weeks between 2 doses), for 6-12 months prior to enrollment.

Exclusion Criteria:

1. Previous medications intervention for the prophylaxis or prevention of COVID-19 (Including vaccination with any licensed SARS-CoV-2 vaccines other than 2 doses of CoronaVac® ).
2. History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) or other coronavirus infections.
3. History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-19.
4. History of allergy to any component of the study vaccine or history of severe allergic reaction to the vaccine or drug (including but not limited to anaphylaxis, allergic laryngeal oedema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction)).
5. Positive nucleic acid for SARS-CoV-2 in nasopharyngeal/oropharyngeal swab specimens.
6. Positive HIV test result.
7. A history or family history of convulsions, epilepsy, encephalopathy and psychosis.
8. Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period.
9. Congenital or functional splenic deficiency, complete or partial splenectomy for any reason.
10. Prolonged (defined as more than 14 days) use of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, ≥20 mg/d prednisone or equivalent; however, inhaled and topical steroids are permitted) within 6 months prior to the vaccine.
11. Any other licensed vaccines given within 28 days prior to the study vaccination, or planned administration of vaccine(s) within 28 days after vaccination.
12. Have received immunoglobulin or other blood products within 3 months prior to enrollment or plan to receive them during the study period.
13. Blood donation or blood loss ≥ 450 mL within 1 month prior to enrolment, or planned donation during the study period.
14. Participants who have received any other investigational product within 1 month prior to enrollment or intent to participate in another clinical study at any time during the conduct of this study.
15. Female participants who are pregnant or breastfeeding.
16. Participants deemed unsuitable for participation in this study based on the investigator's assessment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: LVRNA009 study group	Biological: LVRNA009; 50μg /0.5 mL/Vial/person
ACTIVE_COMPARATOR: CoronaVac® control group	Biological: CoronaVac®; 0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric mean titer (GMT) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)		14 days after vaccination for all participants
Seroconversion Rate (SCR) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)	Seroconversion is defined as: GMT post vaccination≥ 4-fold rise from baseline GMT value	14 days after vaccination for all participants
Incidence of each solicited (local and systemic) AE and each unsolicited AE		AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Intensity of each solicited (local and systemic) AE and each unsolicited AE		AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Duration of each solicited (local and systemic) AE and each unsolicited AE		AE within 14 days, unsolicited AE within 28 days after vaccination for all participants

Secondary Outcome Measures

Outcome Measure	Time Frame
Geometric mean increase (GMI) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)	14 days after vaccination for all participants
GMT of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)	28 days, 3 months, 6 months, and 12 months after vaccination for all participants
SCR of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)	28 days, 3 months, 6 months, and 12 months after vaccination for all participants
GMI of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)	28 days, 3 months, 6 months, and 12 months after vaccination for all participants
GMT of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay)	14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
SCR of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay)	14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
GMI of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay)	14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
GMT of S-protein specific IgG antibodies (ELISA)	14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
SCR of S-protein specific IgG antibodies (ELISA)	14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
GMI of S-protein specific IgG antibodies (ELISA)	14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants
Incidence of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events	within 12 months after vaccination for all participants
Intensity of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events	within 12 months after vaccination for all participants
Causality of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events	within 12 months after vaccination for all participants

Other Outcome Measures

Outcome Measure	Time Frame
Cellular immune subgroup: virus antigen-specific IL-2, IL-4, IL-13, IFN-γ cytokine titers (ELISpot)	7 days, 14 days, and 28 days after vaccination
Cross-neutralization subgroup: cross-neutralizing ability of VNA (live virus neutralizing assay) against other VOCs of SARS-CoV-2	14 and 28 days after vaccination

Collaborators and Investigators

• Sponsor: AIM Vaccine Co., Ltd.
• Investigators: Principal Investigator: Aamer Ikram, National Institute of Health, Islamabad

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): April 1, 2023
• Primary Completion (ANTICIPATED): October 1, 2023
• Study Completion (ANTICIPATED): October 1, 2024

Study Registration Dates

• First Submitted: June 14, 2022
• First Submitted That Met QC Criteria: June 17, 2022
• First Posted (ACTUAL): June 23, 2022

Study Record Updates

• Last Update Posted (ACTUAL): February 2, 2023
• Last Update Submitted That Met QC Criteria: February 1, 2023
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: LVRNA009-Ⅲ-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No